Impact of Universal Screening for HDV in HBV‐ Infected Patients on Chronic HDV Detection Rate in Israel
Journal of Viral Hepatitis · 2025
DOI: 10.1111/jvh.70046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von David Yardeni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Liver Diseases, Soroka University Medical Center, Beersheba, Israel. Hauptthemen laut MEDLINE: Mass Screening, Hepatitis Delta Virus, Hepatitis D, Chronic, Coinfection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatitis delta virus (HDV) and hepatitis B virus (HBV) co‐infection is considered a progressive chronic viral hepatitis where treatment options are limited and significant morbidity and mortality are prevalent. Studies have shown insufficient testing for HDV antibody (anti‐HDV) among HBV‐infected patients. Unlike European and Asian‐Pacific guidelines, the American Association for the Study of Liver Diseases (AASLD) guidelines recommend HDV testing only for high‐risk HBV patients. We evaluated the efficacy of universal vs. risk‐based screening in identifying HDV infection among HBV patients. We performed a retrospective analysis of patients diagnosed with a positive HBsAg in a tertiary medical center and screened for HDV between 2010 and 2022. 761 patients were found to be HBsAg‐positive. 525 (69%) patients met AASLD criteria for HDV screening (high‐risk) and 236 (31%) did not (low‐risk). Universal screening was performed on 559 (73.4%) patients. In the high‐risk group, anti‐HDV positivity was found in 33 patients (8.6%). 17 (51.5%) were found to be HDV RNA‐positive. In the low‐risk group, 4 (2.3%) were found to be anti‐HDV‐positive. None were found to be HDV RNA‐positive. Screening based on AASLD criteria identified only 89% of HDV antibody‐positive patients. During the study period, an increased rate of all‐cause mortality was observed in the AASLD high‐risk group. In this single‐center study, universal screening of HBsAg‐positive patients identified 11% more anti‐HDV‐positive patients in comparison to the AASLD‐supported high‐risk‐only screening recommendations. Due to the paramount importance of HDV detection, universal HDV screening in HBsAg‐positive patients is encouraged.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Liver Diseases, Soroka University Medical Center, Beersheba, Israel.
- Joyce and Irving Goldman Medical School, Faculty of Health Sciences, Beersheba, Israel.
- Clinical Research Center, Soroka University Medical Center, Beersheba, Israel.
- Laboratory of Virology Services, Soroka University Medical Center, Beersheba, Israel.
ORCID-Profile: David Yardeni, Naim Abufreha
Zitieren
APA
Yardeni, D., Cividalli, O., Itkowitz, B., Lipnizkiy, I., Juma'a, A. A., Abufreha, N., Keren-Naus, A., Eisner, N., Shor, A. N., & Etzion, O. (2025). Impact of Universal Screening for HDV in HBV‐ Infected Patients on Chronic HDV Detection Rate in Israel. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70046
Vancouver
Yardeni D, Cividalli O, Itkowitz B, Lipnizkiy I, Juma'a AA, Abufreha N, et al. Impact of Universal Screening for HDV in HBV‐ Infected Patients on Chronic HDV Detection Rate in Israel. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.70046
BibTeX
@article{Yardeni2025,
author = {Yardeni, David and Cividalli, Omer and Itkowitz, Bryan and Lipnizkiy, Inna and Juma'a, Ali Abu and Abufreha, Naim and Keren-Naus, Ayelet and Eisner, Nadav and Shor, Anat Nevo and Etzion, Ohad},
title = {Impact of Universal Screening for HDV in HBV‐ Infected Patients on Chronic HDV Detection Rate in Israel},
journal = {Journal of Viral Hepatitis},
year = {2025},
doi = {10.1111/jvh.70046}
}
EUVIMED